- Home
- RIGL vs CIVB Comparison
RIGL vs CIVB Comparison
Compare RIGL & CIVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | CIVB |
|---|---|---|
| Founded | 1996 | 1884 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 571.6M |
| IPO Year | 2000 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RIGL | CIVB |
|---|---|---|
| Price | $46.86 | $27.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $45.67 | $26.60 |
| AVG Volume (30 Days) | ★ 288.3K | 128.7K |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 2.90% |
| EPS Growth | ★ 1867.68 | 31.34 |
| EPS | 1.32 | ★ 1.41 |
| Revenue | ★ $294,282,000.00 | $19,023,000.00 |
| Revenue This Year | N/A | $14.88 |
| Revenue Next Year | $12.75 | $5.99 |
| P/E Ratio | $35.21 | ★ $19.42 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $19.84 |
| 52 Week High | $52.24 | $29.97 |
Technical Indicators
Market Signals| Indicator | RIGL | CIVB |
|---|---|---|
| Relative Strength Index (RSI) | 66.46 | 37.22 |
| Support Level | $40.05 | $27.00 |
| Resistance Level | $49.10 | $27.48 |
| Average True Range (ATR) | 1.92 | 0.54 |
| MACD | 0.36 | -0.15 |
| Stochastic Oscillator | 90.87 | 16.83 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About CIVB Civista Bancshares Inc.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.